{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:38:13Z","timestamp":1765813093177,"version":"3.48.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,15]]},"DOI":"10.7759\/cureus.99288","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:33:44Z","timestamp":1765812824000},"source":"Crossref","is-referenced-by-count":0,"title":["The Association Between 5\u03b1-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study"],"prefix":"10.7759","author":[{"given":"Chia-Yi","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-Fa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ling","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao Bin","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Ming","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao Kai","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"The endocrine system: an overview","volume":"22","author":"Hiller-Sturmh\u00f6fel S","year":"1998","unstructured":"Hiller-Sturmh\u00f6fel S, Bartke A. The endocrine system: an overview. Alcohol Health Res World. 1998, 22:153-64.","journal-title":"Alcohol Health Res World"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1615\/critreveukargeneexpr.v5.i2.30","article-title":"Androgen action","volume":"5","author":"Roy AK","year":"1995","unstructured":"Roy AK, Chatterjee B. Androgen action. Crit Rev Eukaryot Gene Expr. 1995, 5:157-76. 10.1615\/critreveukargeneexpr.v5.i2.30","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2007.03.004","article-title":"Androgenetic alopecia","volume":"36","author":"Otberg N","year":"2007","unstructured":"Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinol Metab Clin North Am. 2007, 36:379-98. 10.1016\/j.ecl.2007.03.004","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref4","article-title":"Benign prostatic hyperplasia: epidemiology, economics and evaluation","volume":"22","author":"Vuichoud C","year":"2015","unstructured":"Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015, 22:1-6.","journal-title":"Can J Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/npmj.npmj_47_24","article-title":"Androgenetic alopecia: a review","volume":"31","author":"Oiwoh SO","year":"2024","unstructured":"Oiwoh SO, Enitan AO, Adegbosin OT, Akinboro AO, Onayemi EO. Androgenetic alopecia: a review. Niger Postgrad Med J. 2024, 31:85-92. 10.4103\/npmj.npmj_47_24","journal-title":"Niger Postgrad Med J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000112","article-title":"5\u03b1-Reductase inhibitors in androgenetic alopecia","volume":"21","author":"Yim E","year":"2014","unstructured":"Yim E, Nole KL, Tosti A. 5\u03b1-Reductase inhibitors in androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2014, 21:493-8. 10.1097\/MED.0000000000000112","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2020.0843","article-title":"Current treatment for benign prostatic hyperplasia","volume":"117","author":"Miernik A","year":"2020","unstructured":"Miernik A, Gratzke C. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 2020, 117:843-54. 10.3238\/arztebl.2020.0843","journal-title":"Dtsch Arztebl Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/aja202171","article-title":"Sexual, physical, and overall adverse effects in patients treated with 5\u03b1-reductase inhibitors: a systematic review and meta-analysis","volume":"24","author":"Zhang JJ","year":"2022","unstructured":"Zhang JJ, Shi X, Wu T, et al.. Sexual, physical, and overall adverse effects in patients treated with 5\u03b1-reductase inhibitors: a systematic review and meta-analysis. Asian J Androl. 2022, 24:390-7. 10.4103\/aja202171","journal-title":"Asian J Androl"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.200012","article-title":"Health risks associated with long-term finasteride and dutasteride use: it\u2019s time to sound the alarm","volume":"38","author":"Traish AM","year":"2020","unstructured":"Traish AM. Health risks associated with long-term finasteride and dutasteride use: it\u2019s time to sound the alarm. World J Mens Health. 2020, 38:323-37. 10.5534\/wjmh.200012","journal-title":"World J Mens Health"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.04.009","article-title":"Association of 5\u03b1-reductase inhibitors with depression and suicide: a mini systematic review and meta-analysis","volume":"10","author":"Uleri A","year":"2024","unstructured":"Uleri A, Nicolas Cornu J, Gobbo A, Herrmann TR, De Nunzio C, Hashim H, Baboudjian M. Association of 5\u03b1-reductase inhibitors with depression and suicide: a mini systematic review and meta-analysis. Eur Urol Focus. 2024, 10:751-3. 10.1016\/j.euf.2024.04.009","journal-title":"Eur Urol Focus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.91a.23027","article-title":"Medical management of benign prostatic hyperplasia","volume":"91","author":"Haile ES","year":"2024","unstructured":"Haile ES, Sotimehin AE, Gill BC. Medical management of benign prostatic hyperplasia. Cleve Clin J Med. 2024, 91:163-70. 10.3949\/ccjm.91a.23027","journal-title":"Cleve Clin J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-22-1109","article-title":"5\u03b1-reductase inhibitors and risk of kidney and bladder cancers in men with benign prostatic hyperplasia: a population-based cohort study","volume":"32","author":"Doherty N","year":"2023","unstructured":"Doherty N, Cardwell CR, Murchie P, Hill C, Azoulay L, Hicks B. 5\u03b1-reductase inhibitors and risk of kidney and bladder cancers in men with benign prostatic hyperplasia: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2023, 32:428-34. 10.1158\/1055-9965.EPI-22-1109","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2157477","article-title":"Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists","volume":"55","author":"Sheppard J","year":"2023","unstructured":"Sheppard J, Shen Lee B, Periman LM. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Ann Med. 2023, 55:241-52. 10.1080\/07853890.2022.2157477","journal-title":"Ann Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106206","article-title":"Current trends in pharmaceutical treatment of dry eye disease: a review","volume":"175","author":"Mohamed HB","year":"2022","unstructured":"Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA. Current trends in pharmaceutical treatment of dry eye disease: a review. Eur J Pharm Sci. 2022, 175:106206. 10.1016\/j.ejps.2022.106206","journal-title":"Eur J Pharm Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239271","article-title":"Defining dry eye from a clinical perspective","volume":"21","author":"Tsubota K","year":"2020","unstructured":"Tsubota K, Pflugfelder SC, Liu Z, et al.. Defining dry eye from a clinical perspective. Int J Mol Sci. 2020, 21:7. 10.3390\/ijms21239271","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/cxo.12147","article-title":"Sex hormones and the dry eye","volume":"97","author":"Truong S","year":"2014","unstructured":"Truong S, Cole N, Stapleton F, Golebiowski B. Sex hormones and the dry eye. Clin Exp Optom. 2014, 97:324-36. 10.1111\/cxo.12147","journal-title":"Clin Exp Optom"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2174\/1389557033488196","article-title":"Steroid 5alpha-reductase inhibitors","volume":"3","author":"Flores E","year":"2003","unstructured":"Flores E, Bratoeff E, Cabeza M, Ramirez E, Quiroz A, Heuze I. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem. 2003, 3:225-37. 10.2174\/1389557033488196","journal-title":"Mini Rev Med Chem"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin PC","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009, 28:3083-107. 10.1002\/sim.3697","journal-title":"Stat Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2019.02.003","article-title":"Benign prostatic hyperplasia","volume":"46","author":"Langan RC","year":"2019","unstructured":"Langan RC. Benign prostatic hyperplasia. Prim Care. 2019, 46:223-32. 10.1016\/j.pop.2019.02.003","journal-title":"Prim Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2024.04.014","article-title":"Benign prostatic hyperplasia","volume":"163","author":"Infante Hern\u00e1ndez S","year":"2024","unstructured":"Infante Hern\u00e1ndez S, G\u00f3mez Rivas J, Moreno Sierra J. Benign prostatic hyperplasia. Med Clin (Barc). 2024, 163:407-14. 10.1016\/j.medcli.2024.04.014","journal-title":"Med Clin (Barc)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-014-0077-5","article-title":"Androgenetic alopecia: an evidence-based treatment update","volume":"15","author":"Varothai S","year":"2014","unstructured":"Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol. 2014, 15:217-30. 10.1007\/s40257-014-0077-5","journal-title":"Am J Clin Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph192316296","article-title":"The presence of ankylosing spondylitis and the incidence of subsequent external eye diseases: a population-based cohort study","volume":"19","author":"Lee CY","year":"2022","unstructured":"Lee CY, Chen HC, Huang JY, Yen CH, Hwang YS, Chang CK, Yang SF. The presence of ankylosing spondylitis and the incidence of subsequent external eye diseases: a population-based cohort study. Int J Environ Res Public Health. 2022, 19:6. 10.3390\/ijerph192316296","journal-title":"Int J Environ Res Public Health"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2002.tb04217.x","article-title":"Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye","volume":"966","author":"Sullivan DA","year":"2002","unstructured":"Sullivan DA, Sullivan BD, Evans JE, et al.. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002, 966:211-22. 10.1111\/j.1749-6632.2002.tb04217.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012572","article-title":"Sex hormone therapy's effect on dry eye syndrome in postmenopausal women: a meta-analysis of randomized controlled trials","volume":"97","author":"Liu C","year":"2018","unstructured":"Liu C, Liang K, Jiang Z, Tao L. Sex hormone therapy's effect on dry eye syndrome in postmenopausal women: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018, 97:e12572. 10.1097\/MD.0000000000012572","journal-title":"Medicine (Baltimore)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/IJO.IJO_2887_22","article-title":"Hormones and dry eye disease","volume":"71","author":"Gorimanipalli B","year":"2023","unstructured":"Gorimanipalli B, Khamar P, Sethu S, Shetty R. Hormones and dry eye disease. Indian J Ophthalmol. 2023, 71:1276-84. 10.4103\/IJO.IJO_2887_22","journal-title":"Indian J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7754","article-title":"Evaluation of a novel dry eye model induced by oral administration of finasteride","volume":"16","author":"Li K","year":"2017","unstructured":"Li K, Zhang C, Yang Z, Wang Y, Si H. Evaluation of a novel dry eye model induced by oral administration of finasteride. Mol Med Rep. 2017, 16:8763-70. 10.3892\/mmr.2017.7754","journal-title":"Mol Med Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.02.026","article-title":"Prevalence and risk factors of dry eye syndrome in a United States veterans affairs population","volume":"152","author":"Galor A","year":"2011","unstructured":"Galor A, Feuer W, Lee DJ, et al.. Prevalence and risk factors of dry eye syndrome in a United States veterans affairs population. Am J Ophthalmol. 2011, 152:377-84. 10.1016\/j.ajo.2011.02.026","journal-title":"Am J Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60091458","article-title":"Epidemiology and risk factors of dry eye disease: considerations for clinical management","volume":"60","author":"Britten-Jones AC","year":"2024","unstructured":"Britten-Jones AC, Wang MT, Samuels I, Jennings C, Stapleton F, Craig JP. Epidemiology and risk factors of dry eye disease: considerations for clinical management. Medicina (Kaunas). 2024, 60:8. 10.3390\/medicina60091458","journal-title":"Medicina (Kaunas)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1407936","article-title":"Dry eye","volume":"378","author":"Clayton JA","year":"2018","unstructured":"Clayton JA. Dry eye. N Engl J Med. 2018, 378:2212-23. 10.1056\/NEJMra1407936","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2016.07.17","article-title":"Metabolic syndrome risk factors and dry eye syndrome: a meta-analysis","volume":"9","author":"Tang YL","year":"2016","unstructured":"Tang YL, Cheng YL, Ren YP, Yu XN, Shentu XC. Metabolic syndrome risk factors and dry eye syndrome: a meta-analysis. Int J Ophthalmol. 2016, 9:1038-45. 10.18240\/ijo.2016.07.17","journal-title":"Int J Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/441749-the-association-between-5-reductase-inhibitors-and-the-presence-of-subsequent-dry-eye-disease-in-androgenetic-alopecia-a-trinetx-database-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:33:45Z","timestamp":1765812825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/441749-the-association-between-5-reductase-inhibitors-and-the-presence-of-subsequent-dry-eye-disease-in-androgenetic-alopecia-a-trinetx-database-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.99288","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}